financetom
Business
financetom
/
Business
/
Ouster Q2 Loss Narrows, Revenue Rises; Q3 Outlook Set; Shares Slump After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ouster Q2 Loss Narrows, Revenue Rises; Q3 Outlook Set; Shares Slump After Hours
Aug 13, 2024 2:58 PM

05:34 PM EDT, 08/13/2024 (MT Newswires) -- Ouster (OUST) reported a Q2 loss late Tuesday of $0.53 per diluted share, narrowing from the loss of $3.19 a year earlier.

Two analysts polled by Capital IQ expected a loss of $0.63.

Revenue in the quarter ended June 30 rose to $27 million from $19.4 million a year earlier.

Analysts surveyed by Capital IQ expected $27 million.

The company expects Q3 revenue of $27 million to $29 million.

Analysts polled by Capital IQ forecast $30.4 million.

The company's shares fell 17% in after-hours activity.

Price: 9.00, Change: -1.88, Percent Change: -17.28

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sadot Group swings to Q3 net loss 
Sadot Group swings to Q3 net loss 
Nov 19, 2025
Overview * Sadot Group ( SDOT ) Q3 consolidatedrevenue at $0.3 mln, net loss of $15.2 mln * Company reports negative EBITDA of $14.3 mln for Q3 * Sadot Group ( SDOT ) invests in Indonesian carbon project, acquiring 37.5% equity stake in Special Development Group (SDG) Outlook * Company to implement cost-cutting measures and monetize assets * Sadot Group...
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer
Nov 19, 2025
05:09 PM EST, 11/19/2025 (MT Newswires) -- Nuvalent ( NUVL ) said the US Food and Drug Administration accepted the company's new drug application for zidesamtinib to treat adults with advanced ROS1-positive non-small cell lung cancer who have previously received at least one ROS1 tyrosine kinase inhibitor The agency set a Sept. 18 target action date, Nuvalent ( NUVL )...
Primerica Authorizes $475 Million Share Buyback for 2026
Primerica Authorizes $475 Million Share Buyback for 2026
Nov 19, 2025
05:09 PM EST, 11/19/2025 (MT Newswires) -- Primerica ( PRI ) said Wednesday its board authorized a $475 million share repurchase program through Dec. 31, 2026. The company said buybacks may occur in the open market, via block trades or privately negotiated deals, subject to market and regulatory conditions. ...
Chinese courier firm ZTO Express Q3 revenue rises on strong retail volumes
Chinese courier firm ZTO Express Q3 revenue rises on strong retail volumes
Nov 19, 2025
Overview * ZTO Q3 revenue increases 11.1% yr/yr to RMB11.9 bln * Adjusted net income rises 5% to RMB2.5 bln * Parcel volume grows 9.8% to 9.6 bln Outlook * Company revises 2025 parcel volume guidance to 38.2-38.7 bln, up 12.3%-13.8% YoY * ZTO cites macro environment changes for adjusting parcel volume guidance Result Drivers * RETAIL VOLUME GROWTH -...
Copyright 2023-2026 - www.financetom.com All Rights Reserved